Despite near universal availability of nirsevimab, only 35% of eligible children receive nirsevimab for RSV prophylaxis.

Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...

Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial virus prophylaxis, with uptake varying by race and other social factors.

The risk for severe RSV-related outcomes was effectively reduced among children and infants who received nirsevimab in real-world clinical settings.

The team identified more than 7,200 babies eligible to have received nirsevimab during its inaugural 2023-24 RSV season. But ...

John Stewart, Director of Specialised Commissioning at NHS England said: “For babies born very prematurely, the risk of ...

A single, long-lasting jab that offers a “protective bubble” to premature babies from a common virus is set to be rolled out ...

NHS Scotland will offer the new drug to protect babies born before 32 weeks against respiratory syncytial virus.

Today, the Federation of Medical Women of Canada (FMWC) released its latest white paper through the Maternal RSV Task Force—a ...

Premature babies in the UK can now be protected against RSV with a single, long-lasting injection available on the NHS for ...

NHS England » NHS to roll out long-lasting ‘suit of armour’ jab to protect thousands of premature babies from RSV ...